20-F: Compugen Ltd. Files 20-F Report, CGEN Stock Remains Steady

Compugen Ltd. released its annual report on Form 20-F, detailing the company's financial performance and operational activities for the fiscal year ended December 31, 2024.

Summary

• Compugen Ltd., an Israeli clinical-stage therapeutic discovery and development company, has filed its annual report on Form 20-F.
• The report details the company's financial results and operational activities for the fiscal year ended December 31, 2024.
• As of December 31, 2024, Compugen had an accumulated deficit of approximately $488.8 million.
• The company incurred net losses of approximately $14.2 million in 2024, $18.8 million in 2023, and $33.7 million in 2022.
• Revenues for 2024 were approximately $27.9 million, compared to $33.5 million in 2023.
• The company believes its existing cash and investments will be sufficient to fund operations into 2027.
• Compugen's pipeline includes clinical-stage programs such as COM701, COM902, rilvegostomig, and GS-0321 (previously COM503).
• The company is initiating a new adaptive platform trial in relapsed platinum sensitive ovarian cancer in the second quarter of 2025 and expects to share interim analysis data from this sub-trial in the second half of 2026.
• Rilvegostomig, a PD-1/TIGIT bispecific antibody, is being developed by AstraZeneca and is in multiple Phase 3 clinical trials.
• GS-0321 (previously COM503), licensed to Gilead, recently entered a Phase 1 clinical trial with the first patient dosed on January 7, 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company has promising clinical programs and partnerships, it also faces significant financial challenges, including accumulated deficits and ongoing losses. The future outlook is uncertain, and there are several risks associated with the company's operations and the industry in which it operates.

Positives

• The company believes its existing cash and investments will be sufficient to fund operations into 2027.
• Compugen has two ongoing clinical trials (that completed enrollment) that were both initiated in 2023 evaluating the triple combination treatment of COM701, COM902 and pembrolizumab, one in platinum resistant ovarian cancer and the other in microsatellite stable colorectal cancer, both of which have together a few patients on treatment as of the middle of February 2025.
• GS-0321 (previously COM503) recently entered a Phase 1 clinical trial with the first patient dosed on January 7, 2025.
• The company is initiating a new adaptive platform trial in relapsed platinum sensitive ovarian cancer in the second quarter of 2025 and expects to share interim analysis data from this sub-trial in the second half of 2026.
• AstraZeneca is developing rilvegostomig, a PD-1/TIGIT bispecific antibody, which is in multiple Phase 3 clinical trials.

Negatives

• Compugen had an accumulated deficit of approximately $488.8 million as of December 31, 2024.
• The company incurred net losses of approximately $14.2 million in 2024, $18.8 million in 2023, and $33.7 million in 2022.
• Revenues for 2024 were approximately $27.9 million, compared to $33.5 million in 2023.

Risks

• The company has a history of losses and expects to incur future losses.
• Clinical trials may fail to demonstrate safety and/or efficacy.
• The company relies on third parties to conduct clinical trials and manufacture product candidates.
• The company operates in a highly competitive and rapidly changing industry.
• Information technology systems may fail or suffer security breaches.
• The company is subject to stringent and changing obligations related to data privacy and security.
• Patent protection may not be sufficiently broad or may be lost.
• Conditions in Israel and the Middle East may adversely affect operations.
• Exchange rate fluctuations between the dollar and the New Israeli Shekel may adversely affect results of operations.
• Future sales of ordinary shares may depress the share price.
• The company may not be able to meet the continued listing standards of Nasdaq.

Future Outlook

The company believes its existing cash and investments will be sufficient to fund operations into 2027, based on current plans and without considering potential additional funding from licensing agreements or financings.

Industry Context

The report highlights the competitive landscape of the biotechnology and biopharmaceutical industries, particularly in immuno-oncology, noting competition from large pharmaceutical companies, academic institutions, and other research institutions. The report also mentions the increasing interest in applying computational methodologies, such as AI and ML, to drug discovery and development.

Comparison to Industry Standards

• The report mentions that the global immune checkpoint inhibitors market size is estimated at $50.28 billion in 2024 and is anticipated to reach around $229.60 billion by 2034, expanding at a compounded annual growth rate of 16.40% from 2024 to 2034, as reported by Precedence Research.
• The report notes that response rates to current immunotherapies average approximately between 15% to 30% overall, and by some reports 20%-40%, highlighting the unmet medical need for patients who do not respond to these therapies.
• The report mentions clinical trial failures of novel agents in the immuno-oncology field may adversely impact the ability to sign collaborations, and as a result the company may be required to advance programs into clinical development and show clinical proof of concept before attracting potential collaborators, or the company will need to discontinue the programs development.

Stakeholder Impact

• Shareholders may experience dilution if the company issues additional equity securities.
• Employees may be affected by changes in the company's financial condition and strategic direction.
• Customers and collaborators may be impacted by the success or failure of the company's clinical programs.
• Suppliers and creditors may be affected by the company's ability to meet its financial obligations.

Next Steps

• Initiate a new adaptive platform trial in relapsed platinum sensitive ovarian cancer in the second quarter of 2025.
• Share interim analysis data from the COM701 adaptive platform trial in the second half of 2026.
• Continue clinical development of COM701, COM902, and GS-0321 (previously COM503).
• Seek additional collaborations for novel targets and drug product candidates.

Key Dates